GENEVA, Switzerland – November 2018: The World Health Organization (WHO) evaluates the dependence-producing properties and potential harm to health of psychoactive substances. Recommendations from the WHO regarding international control under the International Drug Control Conventions are made to the Secretary-General of the United Nations and are subject to a vote by the United Nations Commission on Narcotic Drugs (CND).

Ten new psychoactive substances (NPS) will be considered for review at the 41st meeting of the WHO Expert Committee on Drug Dependence (ECDD), including five fentanyl analogues, four synthetic cannabinoids and one (meth)cathinone. In addition to the ten NPS, the ECDD will review two substances used in medicine, Tramadol (a synthetic opioid) and Pregabalin, as well as cannabis and cannabis related-substances. The ECDD meeting will be held in Geneva from 12-16 November 2018. 

Fentanyl analogues
Cyclopropylfentanyl
Methoxyacetylfentanyl
Ortho‐fluorofentanyl (2-Fluorofentanyl)
Parafluoro butyrfentanyl (4-Fluorobutyrfentanyl)
Paramethoxybutyrfentanyl (4-Methoxybutyrfentanyl)

Synthetic cannabinoids
ADB-FUBINACA 
FUB‐AMB (MMB‐FUBINACA, AMB‐FUBINACA) 
ADB‐CHMINACA 
CUMYL‐4CNBINACA

Synthetic cathinone
N‐ethylnorpentylone (Ephylone)

Medicines
Tramadol
Pregabalin 

Cannabis and cannabis-related substances
Cannabis plant and resin 
Extracts and tinctures of cannabis 
Delta‐9‐Tetrahydrocannabinol  
Isomers of THC

For more information, please see:

https://www.who.int/medicines/access/controlled-substances/ecdd_41_meeting/en/